Dance Biopharm plans to price initial public offering of common stock

Wells Fargo Securities and Stifel, Oppenheimer and Roth Capital assist

By Devika Patel

Knoxville, Tenn., April 9 - Dance Biopharm, Inc. will conduct an initial public offering of its common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Wells Fargo Securities LLC and Stifel Nicolaus & Co. Inc. are the joint bookrunning managers. Oppenheimer & Co. and Roth Capital Partners are the co-managers.

Proceeds will be used to prepare for and conduct a global phase 3 clinical program for Dance 501, to scale-up and optimize the company's manufacturing processes, for working capital and for other general corporate purposes, including development of product enhancements related to the company's next product version.

The biopharmaceutical company is based in Brisbane, Calif. It intends to list its common stock on the Nasdaq under the symbol "DNCE."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.